Because nonalcoholic steatohepatitis (NASH) is associated with impaired liver regeneration, we investigated the effects of G49, a dual glucagon-like peptide-1/glucagon receptor agonist, on NASH and hepatic regeneration. C57Bl/6 mice fed chow or a methionine and choline-deficient (MCD) diet for 1 week were divided into 4 groups: control (chow diet), MCD diet, chow diet plus G49, and M1G49 (MCD diet plus G49). Mice fed a high-fat diet (HFD) for 10 weeks were divided into groups: HFD and H1G49 (HFD plus G49). Following 2 (MCD groups) or 3 (HFD groups) weeks of treatment with G49, partial hepatectomy (PH) was performed, and all mice were maintained on the same treatment schedule for 2 additional weeks. Analysis of liver function, hepatic regeneration, and comprehensive genomic and metabolic profiling were conducted. NASH was ameliorated in the M1G49 group, manifested by reduced inflammation, steatosis, oxidative stress, and apoptosis and increased mitochondrial biogenesis. G49 treatment was also associated with replenishment of intrahepatic glucose due to enhanced gluconeogenesis and reduced glucose use through the pentose phosphate cycle and oxidative metabolism. Following PH, G49 treatment increased survival, restored the cytokine-mediated priming phase, and enhanced the proliferative capacity and hepatic regeneration ratio in mice on the MCD diet. NASH markers remained decreased in M1G49 mice after PH, and glucose use was shifted to the pentose phosphate cycle and oxidative metabolism. G49 administered immediately after PH was also effective at alleviating the pathological changes induced by the MCD diet. Benefits in terms of liver regeneration were also found in mice fed HFD and treated with G49. Conclusion: Dual-acting glucagon-like peptide-1/glucagon receptor agonists such as G49 represent a novel therapeutic approach for patients with NASH and particularly those requiring PH. (HEPATOLOGY 2017;65:950-968).
N onalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease encompassing conditions from benign steatosis to nonalcoholic steatohepatitis (NASH), which is characterized by lobular and portal inflammation, hepatocyte ballooning, and variable degrees of fibrosis, cirrhosis, and can ultimately lead to hepatocellular carcinoma. (1) Because 15%-20% of patients with NAFLD progress to NASH, millions of people are at risk of suffering cirrhosis and hepatocellular carcinoma, potentially requiring liver transplantation. (2) The causes of progression from steatosis to NASH remain unclear, but lipotoxicity, oxidative stress, and activation of the immune system play key roles. (3) In the liver, parenchymal cells, normally arrested in G 0 , can be induced to proliferate following surgical resection, culminating in a rapid restoration of the hepatic parenchyma. (4) Partial hepatectomy (PH) is an alternative to liver transplantation as it induces hepatic regeneration and repopulation of the damaged liver with healthy hepatocytes. Despite the lack of randomized clinical trials comparing PH and liver transplant, (5) PH circumvents organ shortage and long waiting periods associated with disease progression, being highly relevant for hepatocellular carcinoma patients. (6) According to the scientific registry of transplant recipients, (7) NASH-related cirrhosis is currently the third most common indication for liver transplantation in the United States, surpassed only by hepatitis C virus and alcohol-related cirrhosis. In addition, PH is a potentially curative treatment for patients with resectable liver tumors, (8) but as liver regeneration is impaired in NASH patients, (9) new therapeutic approaches are needed to spur a controlled regenerative response of the liver in this pathological condition. Another key issue is the preservation of the quality of live donor livers available for transplantation, (2) reinforcing the urgent need for efficient therapies against NASH.
Gut hormone-based therapies, particularly those targeting the glucagon like peptide-1 (GLP-1) receptor (GLP-1R) are new drugs for the treatment of type 2 diabetes mellitus. (10) Reductions in GLP-1R in human NASH livers and rats fed a high-fat diet (HFD) have been reported. (11) A clinical study in NASH patients treated with the GLP-1R agonist liraglutide for 12 weeks showed decreased circulating lipotoxic and proinflammatory mediators, resulting in increased insulin sensitivity and metabolic improvement. (12) Also, the LEAN study has reported that treatment with liraglutide for 48 months was safe, was well tolerated, and led to histological resolution of NASH. (13) Recently, it has been shown that hepatic glucose metabolism is essential for energy supply during liver regeneration in mice. (14) In the liver, hepatic glucose production is regulated by glucagon receptor (GCGR)-mediated signaling. (15) Among incretins, oxyntomodulin (OXM) is a dual agonist of GLP-1R and GCGR, although with reduced affinity compared to the single agonists GLP-1 and glucagon, respectively. (16) OXM reduces body weight in humans and rodents and improves glucose metabolism in mice, (17) although the short half-life in circulation limits its therapeutic utility. (18) Thus, stable and potent dual GLP-1R/GCGR agonists have been developed to overcome the limitations of OXM. (19, 20) However, the efficacy of OXM at slowing NAFLD progression has not been tested in either humans or animal models. We hypothesized that the GCGR component of OXM might augment the GLP-1 actions on hepatic metabolism, mitochondrial integrity, and inflammation during liver regeneration in the setting of NASH. To test this, we evaluated the efficacy of G49, a synthetic long-acting analogue of OXM and a dual-acting agonist of GLP-1R and GCGR, at improving liver histology, postoperative liver failure (PLF), and liver regeneration during NASH in mice.
Materials and Methods
A description of methods is available in the Supporting Information.
G49, ANIMALS, DIETS, PH, AND TREATMENTS

G49
(HSQGTFTSDYSKYLEEEAVRLFIC[40 kDa PEG]WLMNT-amide acetate salt; MedImmune Ltd., Cambridge, UK) is a pegylated analogue of OXM exhibiting dual GLP-1R/GCGR agonist activity. The peptide is pegylated with a 40-kDa polyethylene glycol moiety to extend circulation lifetime (Supporting Table  S1A ). (21) Eight-week-old male C57Bl/6 mice were fed chow or a methionine and choline-deficient diet (MCD; TD-90262; Harlan-Teklad, Indianapolis, IN) for 1 week, at which time liver damage was already established (Supporting Fig. S1 ). (22) Mice were subsequently divided into four groups: mice that continued receiving the chow diet for 2 additional weeks (C), mice fed the chow diet and subcutaneously injected with G49 (4.4 mg/kg every 2 days; C1G49), mice that continued with the MCD diet, and mice fed the MCD diet and injected with G49 (M1G49). Both the C and MCD groups were injected with vehicle (saline). Then, mice were subjected to 70% PH as described, (23) after which they were maintained on a similar diet and G49 treatment. Mice were sacrificed at different time periods after PH, and livers were removed, weighed, and normalized to body or brain weight. In an intervention experiment, mice were fed the MCD diet for 3 weeks to establish more advanced NASH and then PH was performed. Immediately after PH, mice were divided into four groups: mice switched to the chow diet for 2 additional weeks (C), mice fed the chow diet and subcutaneously injected with G49 (4.4 mg/kg every 2 days; C1G49), mice that continued with the MCD diet, and mice fed the MCD diet and injected with G49 (M1G49). The C1G49 and M1G49 groups received the first G49 injection immediately after PH, whereas the C and MCD groups were injected with vehicle.
Another cohort of mice were fed HFD (60% calories from fat; TD-06414) for 10 weeks, injected with G49 (H1G49) or vehicle (HFD) for 3 additional weeks, and subjected to 70% PH, after which they were maintained on the same diet and G49 treatment. An intervention group (H1G49 INT) was fed the HFD for 13 weeks and injected with G49 immediately after PH. Mice were sacrificed 2 weeks post-PH.
Results
TREATMENT WITH G49 IMPROVES NASH FEATURES IN MICE
The agonist potencies (median effective concentration values) of G49 at mouse and human GLP-1R and GCGR are shown in Supporting Table S1B. Mice fed the MCD diet for 3 weeks presented anticipated features of NASH with intrahepatic triglyceride (TG) accumulation, elevated alanine aminotransferase (ALT), and increased NAFLD activity score (NAS) compared to mice fed chow (Fig. 1A,B) . Treatment with G49 (M1G49) ameliorated liver damage, with a NAS comparable to that of the control group. Moreover, the decrease in circulating TG in the MCD group, due to reduced secretion by the liver, (24) was partly reverted in the M1G49 group (Supporting Fig. S1 ).
We performed microarray gene expression analysis to gain biological insight about the pathways altered in livers of mice fed the MCD diet that were affected by G49 treatment. For gene set enrichment analysis, we used the Kyoto Encyclopedia of Genes and Genomes and REACTOME pathway databases. Analyzing the Kyoto Encyclopedia of Genes and Genomes, 106 gene sets were up-regulated and 28 down-regulated in MCD diet-fed mice with respect to M1G49 mice; and, among them, 27 pathways were significantly enriched in MCD, while four were significantly enriched in M1G49 mice (false discovery rate [FDR] <0.250). REACTOME revealed 234 up-regulated and 57 down-regulated collections, 72 of them significantly enriched in MCD and 3 in M1G49 mice (FDR <0.250). Inflammation, cell cycle, endoplasmic reticulum (ER) stress, p53, G protein-coupled receptor, apoptosis, hemostasis, and retinol metabolism gene families were up-regulated in the MCD versus the M1G49 group ( Fig. 1C ; Supporting  Fig. S2 ), suggesting that multiple pathways involving liver function and metabolism were dysregulated in the NASH group and modulated by G49.
Based on the microarray data, we analyzed inflammatory markers. Elevations in intrahepatic and circulating proinflammatory cytokines ( Fig. 1D ; Supporting , and glycogen depots (red arrows) and quantification of the number of mitochondria per field. *P < 0.05, **P < 0.01, ***P < 0.001 versus C group; ## P < 0.01, ### P < 0.001 versus MCD group according to one-way analysis of variance with post hoc Bonferroni test (n 5 10-12 mice/group). Abbreviation: GPCR, G protein-coupled receptor; H&E, hematoxylin and eosin; LD, lipid droplet.
by Adgre1 (encoding F4/80) mRNA levels and immunohistochemistry (Fig. 1D,E) , were found exclusively in the MCD group. Electron microscopy showed lipid droplets, accumulation of autophagosomes, and dilated ER in livers from mice fed the MCD diet but not in the M1G49 group (Fig. 1F) . Moreover, the number of mitochondria per field (Fig. 1F ) and mRNA levels of mitochondrial biogenesis regulatory genes (Pgc1a, CoxIV, and Tfam) were significantly higher in M1G49 mice (Supporting Fig. S3 ). In this group, decreased apoptosis, assessed by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL), compared to the MCD group paralleled with increased activity of antioxidant enzymes (glutathione peroxidase and glutathione reductase), elevated glutathione (GSH) and decreased protein carbonylation (Supporting Fig. S3 ).
G49 INCREASES GLUCOSE AVAILABILITY IN MICE FED THE MCD DIET
Because microarray analysis revealed up-regulation of genes involved in glucose transport including the main glucose transporter in the liver, Slc2a (which encodes GLUT2), and down-regulation of glycolysisrelated genes in the M1G49 versus the MCD group ( Fig. 2A) , we next measured intrahepatic glucose and glycogen levels. Both were decreased in MCD versus control (C) mice but significantly increased in the M1G49 group, reaching levels detected in the controls (Fig. 2B,C) . Intrahepatic free glucose was also measured, and the highest levels were detected in the M1G49 group, reflecting increased glucose availability (Fig. 2B) . Moreover, in the latter group, mRNA levels of Pck1, but not G6pc, were increased (Fig. 2D) . By contrast, the activity of glucose 6-phosphate dehydrogenase (G6PDH), a rate-limiting enzyme of the pentose phosphate cycle (PPC), was decreased in both MCD and M1G49 groups compared to the controls (Fig. 2E ). The metabolomic analysis ( Fig. 2F ; Supporting Table S2 ) was consistent with these findings based on increases in hepatic glucose and glucose 6-phosphate and a strong decrease in pyruvate and other tricarboxylic acid (TCA) cycle metabolites. Moreover, this analysis revealed an inhibition of the PPC and, interestingly, an increase of several metabolites implicated in the methionine recycling pathway. This scenario suggests that G49 targets hepatic glucose metabolism by increasing glucose uptake and glucose production and shifts the intrahepatic glucose pool toward glycogen synthesis.
G49 REDUCED PLF AND INCREASED HEPATIC REGENERATION DURING NASH
After observing the beneficial effects of G49 in ameliorating NASH, we investigated its effect on liver regeneration after 70% PH (Supporting Fig. S1 ). In mice fed either chow or the MCD diet, treatment with G49 significantly reduced PLF, manifested by increased percentage of survival after PH (Fig. 3A) . Only 40% of mice fed the MCD diet survived at 72 hours post-PH, whereas in the M1G49 group the survival rate reached 64%, which was comparable to that of mice on the chow diet.
Two weeks after PH, mice on the MCD diet showed a statistically significant reduction in liver regeneration assessed by liver-to-body weight ratio (Fig. 3B) . Interestingly, G49 normalized liver regeneration in the M1G49 group to levels observed in the C and C1G49 groups. To account for body weight differences induced by G49 (Supporting Fig. S4 ), the liver regeneration ratio was normalized to the liver-tobrain weight ratio. M1G49 also caused a significant increase in the liver regeneration ratio compared to the MCD group.
Insulin released by pancreatic beta-cells is another trigger for hepatocyte proliferation after PH. (25) Plasma insulin was increased in the C1G49 group compared to C mice and was decreased in MCD diet-fed mice, this effect being significantly ameliorated in the M1G49 group (Supporting Fig. S4 ). In contrast, G49 treatment reduced plasma glucagon in both the chow and MCD groups. Reduced glucose levels were seen following MCD diet as noted in earlier reports, (26) and glycemic levels were further reduced by G49 treatment.
To monitor the balance between cell proliferation and death immediately after PH, (4) bromodeoxyuridine (BrdU) incorporation, proliferating cell nuclear antigen levels, and apoptosis were measured. Surprisingly, in mice fed the MCD diet, both BrdU incorporation and proliferating cell nuclear antigen levels were elevated at 48 hours post-PH, probably due to a compensatory response of the liver to increase regeneration (Fig. 3C,D) . However, the significant increase in TUNEL-positive cells in these mice resulted in a decreased BrdU/TUNEL ratio. Conversely, in M1G49 mice we found an increased BrdU/TUNEL ratio versus the MCD and C groups in favor of cell proliferation. We also analyzed the priming phase of hepatic regeneration by measuring the circulating levels of proinflammatory cytokines released by the liver immediately after PH (1-48 hours). Circulating interleukin-1b remained unchanged in the MCD group, whereas in M1G49 mice a transient peak was observed at 3 hours post-PH that declined at 6 hours, showing a similar priming profile found in the C and C1G49 groups (Fig. 3E) . Likewise, circulating tumor necrosis factor alpha did not change in MCD mice, but in the M1G49 group a marked transient priming peak was found at 6 hours post-PH. Regarding interleukin-6, a plateau was found in the MCD group, whereas a peak at 6 hours post-PH occurred in the M1G49 group. At the molecular level, priming in the M1G49 group was manifested by elevations in c-Jun N-terminal kinase (JNK) and signal transducer and activator of transcription 3 phosphorylation compared with levels detected in the MCD group (Fig. 3F) .
THE BENEFICIAL EFFECTS OF G49 IN MICE FED THE MCD DIET WERE MAINTAINED 2 WEEKS AFTER PH
Two weeks after PH, surviving mice in the MCD group displayed increased features of NASH as evidenced by elevated NAS, plasma ALT, and intrahepatic TG accumulation ( Fig. 4A; Supporting Fig. S5 ). However, none of these alterations were found in the M1G49 group, and we observed a reduced degree of steatosis and inflammation. Importantly, plasma concentrations of G49 were detected 48 hours after the last injection in both G49-injected groups (Supporting Fig. S5 ). The reduction in GLP-1R mRNA in MCD mice (Fig. 4B) confirmed the reported decreases in human NASH, (11) but this effect was absent in the M1G49 group. GCGR mRNA was down-regulated by NASH in mice (Fig. 4B) , and G49 was also able to increase hepatic GCGR expression in the M1G49 group. Interestingly, GCGR mRNA was decreased in humans with fatty liver and NASH (Fig. 4C) as occurred with GLP-1R mRNA. (11) Furthermore, the robust increase in hepatic Fgf21 mRNA detected in mice fed the MCD diet (Fig. 4B) , as described, (27) was markedly attenuated with G49 treatment. In agreement with Mutanen et al., (28) Fgf21 mRNA was found elevated in livers from patients with NAFLD (Fig.  4C) .
We performed microarrays in liver samples 2 weeks post-PH. Analyzing the Kyoto Encyclopedia of Genes and Genomes, 93 gene sets were up-regulated and 41 down-regulated in MCD mice compared to M1G49 treatment and, among them, 20 pathways were significantly enriched in MCD, while 6 were significantly enriched in M1G49 mice (FDR <0.250) (Supporting Fig. S6 ). REACTOME showed 253 up-regulated and 248 down-regulated collections, 41 of them with FDR <0.250 in MCD but only 1 with a significant modulation in M1G49 mice. The inflammation-related gene family was also up-regulated 2 weeks post-PH in mice fed the MCD diet compared to the M1G49 group (Fig. 4D) . Analysis of inflammatory cytokines in liver and plasma and F4/80 immunostaining in liver sections confirmed persistent hepatic inflammation in the MCD, but not in the M1G49, group ( Fig. 4E ; Supporting Fig. S5 ). Moreover, hepatic stellate cell (HSC) activation, assessed by elevations of Col1a, aSma, and Desmin mRNAs and by sirius red and desmin immunostaining, was found exclusively in MCD diet-fed mice (Fig. 4F) .
Among gene families down-regulated in the M1G49 versus the MCD group (Supporting Fig.  S6 ), the changes in cell death and senescence gene families (Fig. 5A) were confirmed by decreased TUNEL-positive cells (Fig. 5B) , increased GSH levels and antioxidant defenses, and decreased protein carbonylation in the M1G49 versus the MCD group (Supporting Fig. S5 ). Interestingly, gene families that were up-regulated in the M1G49 versus MCD group included mitochondrial function (oxidative phosphorylation, mitochondrial protein import, and TCA family genes), amino acids, and glycerolipid metabolism gene families (Fig. 5C,D) . In the electron microscopic Italics indicate additional metabolites analyzed as described in Materials and Methods. **P < 0.01, ***P < 0.001 versus C group; # P < 0.05, ## P < 0.01, ### P < 0.001 versus MCD group according to one-way analysis of variance with post hoc Bonferroni test (n 5 8-10 mice/ group). Abbreviations: AMP, adenosine monophosphate; Arg, arginine; Arg Suc, arginine succinate; Asp, aspartate; CoA, coenzyme A; DHAP, dihydroxyacetone phosphate; E4P, erythrose 4-phosphate; FFA, free fatty acid; F1,6-BP, fructose 1,6-bisphosphate; F6P, fructose 6-phosphate; G3P, glycerol 3-phosphate; G6P, glucose 6-phosphate; GA3P, glyceraldehyde 3-phosphate; HCys, homocysteine; aKG, alpha-ketoglutaric acid; 5MTHF, 5-methyltetrahydrofolate; OA, oxaloacetic acid; Orn, ornithine; 3-PG, 3-phosphoglyceric acid; 6P-GL, 6 phosphogluconolactone; PAS, periodic acid-Schiff; PEP, phosphoenolpyruvate; R5P, ribose 5-phosphate; SAH, S-adenosyl homocysteine; SAM, S-adenosyl methionine; SH7P, sedoheptulose 7-phosphate; THF, tetrahydrofolate; X5P, xylulose 5-phosphate. analysis of livers collected 2 weeks post-PH, mitochondrial swelling was detected in the MCD group, whereas mitochondrial integrity was preserved in M1G49 mice (Fig. 5E ). This beneficial effect of G49 on mitochondria was confirmed by elevations in Pgc1a, CoxIV, and Tfam mRNAs and by the increased number of mitochondria per field, which was also elevated in the C1G49 versus C group (Fig. 5F ). Likewise, reduced ER dilatation and down-regulation of the unfolded protein response and XBP-1-activated chaperone gene families were found in M1G49 compared to MCD mice in parallel to reductions in the accumulation of autophagosomes (Supporting Fig. S7 ).
TREATMENT WITH G49 INCREASES GLUCOSE AVAILABILITY AFTER PH
Intrahepatic glucose levels were determined 2 weeks after PH; and in contrast with the situation before PH (Fig. 2B) , total glucose and glycogen contents were lower in M1G49 versus MCD mice, and only intrahepatic free glucose was higher in the M1G49 versus MCD group (Fig. 6A) . Whereas Pck1 and Gk mRNAs were significantly increased in M1G49 mice compared to MCD mice, G6pc mRNA was decreased and G6PDH enzymatic activity was elevated (Fig. 6B,C) .
The metabolomic analysis performed at 2 weeks post-PH ( Fig. 6D ; Supporting Table S3 ) revealed upregulation of glycolysis, TCA, and PPC fluxes in the M1G49 versus the MCD group. As occurred before PH, an increase in the methionine recycling pathway was detected in the M1G49 group. Altogether, these data suggest enhanced gluconeogenesis and intrahepatic glucose use toward oxidative metabolism and PPC in M1G49 mice after PH that might serve to enhance proliferation of liver cells and/or detoxification processes. In fact, up-regulation of the peroxisome metabolism gene family and increased number of peroxisomes were found in the M1G49 group (Fig.  6E,F) .
AN INTERVENTION PROTOCOL WITH G49 IMPROVES PLF AND NASH DURING HEPATIC REGENERATION IN MICE
We designed an intervention protocol with G49 (see Materials and Methods; Supporting Fig. S8 ). Chow-fed and MCD diet-fed mice were treated with G49 by receiving the first injection immediately after PH. PLF, determined by the survival of mice 72 hours post-PH, was ameliorated in both groups receiving G49 (Fig. 7A) . Two weeks post-PH, the liver regeneration ratio was significantly increased by G49 treatment in both chow-fed and MCD diet-fed mice (Fig.  7B) . NAS increased in the MCD group commensurate with higher ALT activity and intrahepatic TG content (Fig. 7C) , all of these parameters being reduced in the M1G49 group. Notably, mice fed the chow diet during the liver regeneration period (C group) recovered from NASH regardless of the treatment with G49, although in the C1G49 group a significant increase in liver regeneration ratio was observed (Fig. 7B) . Proinflammatory and HSC activation markers and the number of apoptotic cells ( Fig. 7D,E; Supporting Fig. S8 ) were reduced in M1G49 versus MCD mice, whereas the number of mitochondria and mRNA levels of Pgc1a, CoxIV, and Tfam were increased (Fig. 7F ).
G49 IMPROVED LIVER REGENERATION IN DIET-INDUCED OBESE MICE
G49, administered to HFD-fed mice for 3 weeks, decreased body weight, plasma insulin, and glucagon and improved glucose intolerance and insulin and JNK at 1-6 hours after PH. *P < 0.05, **P < 0.01, ***P < 0.001 versus C group; ## P < 0.01, ### P < 0.001 versus MCD group according to one-way analysis of variance with post hoc Bonferroni test (n 5 6 mice/group). Abbreviations: BrdU, bromodeoxyuridine; IL, interleukin; MW, molecular weight; PCNA, proliferating cell nuclear antigen; PI3K, phosphoinositide 3-kinase; P-STAT3, phosphorylated signal transducer and activator of transcription 3; TNF, tumor necrosis factor. (E) Representative transmission electron microscopic images of livers 2 weeks after PH. (F) Hepatic mRNA levels of genes related to mitochondrial biogenesis and quantification of mitochondria per field. *P < 0.05, **P < 0.01, ***P < 0.001 versus C group; # P < 0.05, ## P < 0.01, ### P < 0.001 versus MCD group according to one-way analysis of variance with post hoc Bonferroni test (n 5 10-12 mice/group). Abbreviations: AA, amino acid; GL, glycerolipid; Mito., mitochondrial; OXPHOS, oxidative phosphorylation. sensitivity (Supporting Fig. S9 ). As occurred in the MCD model, intrahepatic glucose stores were decreased in the HFD group compared to the C group, and G49 prevented this effect by increasing Pck1 mRNA (Fig. 8A) . When G49-treated mice were subjected to PH, the survival ratio after PH was increased and the decrease in the regeneration ratio found in the HFD group was prevented (Fig. 8B) . NAS, intrahepatic TG, infiltration of macrophages, and mRNA levels of proinflammatory cytokines and lipogenic genes were reduced by G49 treatment, whereas G49 treatment increased mRNAs of fatty acid oxidation genes (Fig. 8C-F) . The beneficial effects of G49 were also observed in the intervention protocol (H1G49 INT) by administration of G49 immediately after PH (Fig. 8B-E ).
Discussion
Our findings provide strong evidence that supports the potential use of dual GLP-1R and GCGR agonists such as G49 for treatment of NASH, as well as for improvement of PLF and liver regeneration. The beneficial effect of OXM, a GLP-1R/GCGR dual agonist, on body weight loss in obese patients (29) and rodents (30, 31) has been reported; but our study describes the effects of an OXM derivative in a rodent model of NASH. To our knowledge, there is only one recent report describing the beneficial effect of GLP-1 on apoptotic and oxidative markers after PH in rats. (32) Experimental models that mimic human NASH serve as a preclinical platform to evaluate novel therapeutic strategies that are urgently needed due to the limitations of lifestyle interventions in preventing disease progression.
(1) In this study, mice fed the MCD diet were used as a model of NASH. (33) In mice with established NASH, treatment for 2 weeks with G49 prevented the hepatic histopathological features of this disease by targeting multiple biological processes, as will be discussed below (Figs. 1 and 2) .
The MCD diet induces a general lipodystrophy that increases the flux of free fatty acids to the liver, (27) resulting in oxidative stress and hepatocyte lipoapoptosis, which induce the recruitment and/or activation of macrophages. (34) The beneficial effect of G49 on lipoapoptosis and subsequent hepatic inflammation may be partly due to its ability to target oxidative stress and mitochondria. Oxidative stress due to excessive lipid accumulation is critical in triggering the progression from steatosis to NASH. (35) Elevation of reactive oxygen species increases the inflammation-mediated JNK and nuclear factor jB signaling pathways, ultimately leading to apoptotic cell death of hepatocytes. (36) Treatment of NASH with G49 targeted the redox balance of the liver by replenishment of GSH stores and the induction of antioxidant defenses, both likely responsible for the reduction of carbonylated proteins. Furthermore, G49 increased mitochondrial biogenesis-related genes and up-regulated the methionine cycle in livers of M1G49 versus MCD mice, which depends on the recycling of methyl donors in this organelle. (37) In the liver, GCGR-mediated signaling is sensitive to fasting and activates glycogenolysis and gluconeogenesis to maintain whole-body glucose homeostasis. Moreover, it has been reported that GLP-1R signaling increases glycogen storage. (38) In mice fed the MCD diet, glucose storage (glycogen and free intrahepatic glucose) was significantly reduced compared to control mice, but, interestingly, levels in the M1G49 group were higher than those in the MCD group. This suggests that G49, acting through the GCGR, shifts intrahepatic glucose metabolism toward gluconeogenesis, albeit due to its GLP-1R agonism, de novo synthesized glucose is likely being used to increase glycogen storage. This effect might be facilitated by an increase Italics indicate additional metabolites analyzed as described in Materials and Methods. (E) Transmission electron microscopic images and quantification of peroxisomes per field. (F) Genes related to peroxisome activity up-regulated (P < 0.001) in M1G49 versus MCD animals. *P < 0.05, **P < 0.01, ***P < 0.001 versus C group; # P < 0.05, ## P < 0.01, ### P < 0.001 versus MCD group according to one-way analysis of variance with post hoc Bonferroni test (n 5 8-10 mice/group). Abbreviations: AMP, adenosine monophosphate; Arg, arginine; Arg Suc, arginine succinate; Asp, aspartate; CoA, coenzyme A; DHAP, dihydroxyacetone phosphate; E4P, erythrose 4-phosphate; FFA, free fatty acid; F1,6-BP, fructose 1,6-bisphosphate; F6P, fructose 6-phosphate; G3P, glycerol 3-phosphate; G6P, glucose 6-phosphate; GA3P, glyceraldehyde 3-phosphate; HCys, homocysteine; aKG, alpha-ketoglutaric acid; 5MTHF, 5-methyltetrahydrofolate; OA, oxaloacetic acid; Orn, ornithine; 3-PG, 3-phosphoglyceric acid; 6P-GL, 6 phosphogluconolactone; PAS, periodic acid-Schiff; PEP, phosphoenolpyruvate; R5P, ribose 5-phosphate; SAH, S-adenosyl homocysteine; SAM, Sadenosyl methionine; THF, tetrahydrofolate; X5P, xylulose 5-phosphate. in Pck1 mRNA in parallel to a down-regulation of G6pc mRNA in M1G49 versus MCD mice that probably impedes glucose output. Moreover, metabolomics and decreased G6PDH activity demonstrated an inhibition of PPC in M1G49 animals, reinforcing this metabolic scenario in favor of storage of the de novo synthesized glucose as glycogen. The high prevalence of NASH detected in hepatic surgery in humans, (7) together with the beneficial effect of G49 found in our study, prompted us to evaluate its efficacy in liver regeneration during NASH. MCD diet-induced NASH caused a worse outcome posthepatectomy compared to control mice, resembling the postoperative complications and death reported in human NAFLD subjects undergoing partial hepatic resection. (39) Treatment with G49 improved postoperative survival in mice fed the chow or MCD diet, which could be explained, at least in part, by the aforementioned metabolic adaptations that augment glucose availability. These data are supported by studies in caveolin-1-deficient mice that point to the availability of glucose as essential for survival immediately after PH. (14) Inflammation controls cell fate during liver regeneration, and in this context, it has dual and opposite effects. An early and transient increase of proinflammatory cytokines is necessary for the exit of hepatocytes from G 0 , (40) but sustained proinflammatory signaling impairs liver regeneration. (41) We show that mice fed the MCD diet lack the priming phase of liver regeneration manifested by the absence of elevations in plasma cytokines and activation of the stress kinases (signal transducer and activator of transcription 3 and JNK) in the liver during the early phases after PH. However, M1G49 mice retained cytokine-mediated priming signaling that likely led to the liver regeneration observed 2 weeks after PH, a time in which humans and mice have already restored liver mass. (40) Notably, in C1G49 mice, the proliferative capacity of hepatocytes immediately after PH was increased without affecting the final liver regeneration ratio, suggesting that these mice might reach the maximum liver regeneration at an early time period. In fact, microarray analysis revealed a down-regulation of proliferationrelated gene families 2 weeks after PH in C1G49 mice compared to the C group (Supporting Fig. S10 ), suggesting that G49 does not compromise the cell cycle checkpoint controls during the regenerative process.
It is likely that both GLP-1R and GCGR contribute to the beneficial effects of G49 on hepatocyte proliferation post-PH because G49 prevented the decrease of their mRNA levels by NASH. This effect of G49 is highly relevant because our results have shown that the drop of GLP-1R reported in human NASH (11) also occurred with the GCGR. In addition, G49, probably mediated by the GCGR, decreased the rate of cell death after the injury of PH, which was particularly elevated in mice fed the MCD diet. In this regard, it has been reported that a threshold level of hepatocyte GCGR signaling is necessary for hepatocellular survival. (42) These results are in agreement with the absence of elevation in Fgf21 mRNA found in the M1G49 group compared to the MCD group. In fact, increased Fgf21 mRNA in mice fed the MCD diet has been suggested to be a physiologic adaptation to hepatic stress. (27) Coordinated glucose metabolism is a prerequisite for normal liver regeneration. It is known that the decrease in liver tissue after PH is accompanied by hormonal changes that increase glycogenolysis and gluconeogenesis in the remnant liver, (43) as well as shift glucose use toward the PPC in order to provide reduced nicotinamide adenine dinucleotide phosphate for lipid and DNA synthesis. (25) For instance, impaired gluconeogenesis was associated with defective liver regeneration in hypoxia inducible factor 1a-deficient mice. (44) In this context, at 2 weeks post-PH total intrahepatic glucose and glycogen declined in mice receiving G49, likely reflecting increased glucose use during the regenerative process. These results were supported by the up-regulation of Gk mRNA, mitochondrial biogenesis, and TCA family genes as well as by elevations in pyruvate and TCA metabolites, Representative transmission electron microscopic images, quantification of mitochondria per field, and hepatic mRNA levels of genes related to mitochondrial biogenesis. *P < 0.05, **P < 0.01, ***P < 0.001 versus C group; # P < 0.05, ## P < 0.01, ### P < 0.001 versus MCD group according to one-way analysis of variance with post hoc Bonferroni test (n 5 6 mice/group). Abbreviation: H&E, hematoxylin and eosin.
FIG. 8.
G49 improved liver regeneration in diet-induced obese mice. (A) Mice were fed chow or HFD for 10 weeks and then divided into three groups as follows: mice that continued receiving chow diet (C), mice injected with vehicle and that continued receiving HFD for 3 additional weeks (HFD), and mice fed HFD treated with G49 (H1G49). (A) Total and free intrahepatic glucose and glycogen levels and mRNA levels of gluconeogenic enzymes. (B) PH was performed in C, HFD, and H1G49 groups described in (A); and mice were sacrificed 2 weeks post-PH. An additional intervention group (H1G49 INT) was fed HFD for 13 weeks and treated with G49 immediately after PH. Survival Kaplan-Meier curves. *P < 0.05 versus C group; # P < 0.05 versus HFD group according to log-rank (Mantel-Cox) test performed 72 hours after PH and regeneration ratio corrected by body or brain weight analyzed 14 days post-PH (n 5 8 mice/group). (C) NAS and representative images of hematoxylin and eosin staining before PH and 14 days after PH. (D) Liver TG content before PH and 14 days after PH. (E) mRNA levels of genes involved in hepatic lipid metabolism analyzed 14 days after PH. (F) Images of F4/80 immunostaining in liver sections before PH and 14 days after PH and mRNA levels of proinflammatory cytokines analyzed 14 days after PH. *P < 0.05, **P < 0.01, ***P < 0.001 versus C group; # P < 0.05, ## P < 0.01, ### P < 0.001 versus HFD group according to one-way analysis of variance with post hoc Bonferroni test (n 5 4-5 mice/group). Abbreviation: H&E, hematoxylin and eosin.
